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Diagnostic criteria were heterogeneous and included deﬁ nitions based on International 
Classiﬁ cation for Headache Disorders (ICHD) guidelines, Silberstein-Lipton criteria, 
and various investigator-deﬁ ned frequency-based classiﬁ cations. Thus, deﬁ nitions
varied from relatively strict criteria (q15 days/month of migraine) to more liberal cri-
teria (history of migraine and q15 days/month of headache). Prevalence of CM was 
0%-5.1%, with estimates typically in the range of 1.4%-2.2%. Seven studies used 
criteria of history of migraine and q15 days/month of headache (or equivalent), with 
prevalence of 0.9%-5.1%. Three studies used criteria of q15 days/month of migraine
(or equivalent), with prevalence of 0%-0.7%. Two studies stated that the condition 
was transformed migraine or chronic migraine (without speciﬁ c criteria), with preva-
lence of 1.6% and 4.1%. Prevalence varied by WHO region and gender. CONCLU-
SIONS: CM prevalence estimates are inﬂ uenced by speciﬁ c deﬁ nitions employed.
Using the strictest criteria, prevalence was well under 1%; with a less restrictive deﬁ ni-
tion, prevalence was higher, 1%-5%. With these variations, it is difﬁ cult to compare 
results across regions and explore temporal trends. Future studies on CM would 
beneﬁ t from an ICHD consensus diagnosis that is clinically appropriate and opera-
tional in large-scale epidemiological studies.
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OBJECTIVES: Prevalence data of Alzheimer’s disease and related dementia (ADRD) 
in managed care organizations (MCO) is old and very few data on the prevalence of 
the co-existing conditions. This study aims at investigating the rates and the trend of 
the prevalence of ADRD and the co-existing conditions in MCO over an eleven- year 
period. METHODS: Data are drawn from the Ingenix Impact National Managed Care 
Database (Impact Database). The study time period is 1997–2007. Annual prevalence
of ADRD and two common co-existing conditions (type II diabetes and congestive 
heart failure) are calculated among those aged q50 and those aged q65. Prevalence of 
the co-existing conditions among ADRD patients are compared to the prevalence
among the general population in the same age group. Data extraction and prevalence
calculations are performed in SAS 9.1. RESULTS: From 1997 to 2001, prevalence of 
ADRD increased dramatically among those aged 50 and aged 65. Prevalence of ADRD 
starts to level off during 2005–2007 in both age groups. For the two co-morbid condi-
tions that are investigated, 1) prevalence of diabetes is 2.3 times higher in ADRD 
patients than in the general population, prevalence of congestive heart failure is 5 
times higher; and 2) during 1997–2007, prevalence of both co-morbid conditions 
among ADRD patients are constantly increasing, whereas the prevalence in the general 
population are variant. CONCLUSIONS: In this study, prevalence estimates of ADRD 
are consistent with the literature. The ﬁ nding that the prevalence of ADRD starts to 
level off since 2005 may indicate that for persons under the care of MCO, the under-
diagnose of ADRD may drop to a certain level in recent years. The substantially higher
prevalence of co-morbid conditions among ADRD patients and its constantly increas-
ing trend may pose both challenge and opportunity to MCO managers in their strate-
gies for containing costs.
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OBJECTIVES: Worldwide, data on the long term prognosis of Parkinson’s disease 
(PD) are limited, particularly in South-east Asia. This study was carried out to inves-
tigate the time taken to transit between Hoehn & Yahr (H&Y) stages among patients 
with PD in Singapore. METHODS: Patients were recruited from a tertiary neurosci-
ence clinic in Singapore. Both patients’ clinical and demographic information were
obtained from hospital’s database. Time-to-transition was computed using Kaplan-
Meier analysis. Cox regression analysis was performed to examine the inﬂ uence of 
gender, race, duration of PD and age-at-diagnosis on time-to-transition. RESULTS: A
total of 695 patients (mean age: 65.3, male: 58%) consented to participate in the 
study. Using Kaplan-Meier analysis, the time-to-transition from H&Y stage 1 to 2, 
from 2 to 2.5, from 2.5 to 3 were 22.3, 52.9 and 30.3 months, respectively. Time-to-
transition from stage 3 to 4, and from stage 4 to 5 were 27.4 and 30.0 months, 
respectively. In Cox regression analysis, younger-onset (age at diagnosis  83.6 as refer-
ence group, p  0.006; age at diagnosis  56.1, f p  1.713, p  0.011) and shorter 
PD duration (duration  14.7 as reference group, p  0.002; duration  4.9, f p 
2.188, p  0.001; duration  7.5, f p  1.443, p  0.030) predicted longer time-to-
transition from stage 2 to 2.5. Shorter PD duration (duration  22.8, p  0.021) simi-
larly predicted longer duration from stage 4 to 5. CONCLUSIONS: To the best of 
our knowledge, this is the ﬁ rst study to report on disease progression using time-to-
transition between various H&Y stages. Our ﬁ ndings were similar from current litera-
ture in that younger-onset patients took longer to reach advanced stages. However, 
unlike published literature, disease progression was not slower among female com-
pared to male patients in our study. This could be a real difference or could be due
to different ways of measuring disease progression. The data are thus interesting and 
worth further exploration. These information are also important to clinicians to help
improve patient management.
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OBJECTIVES: To assess the proportion of patients with epilepsy switching back to 
branded lamotrigine after generic substitution, to investigate the possible clinical 
consequences of generic substitution in Germany, and to compare the results with 
published research data. German national guidelines recommend not to switch stable
epileptic patients to a generic version of the anti-epileptic drug (AED). METHODS:
Retrospective IMS Disease Analyzer with longitudinal data (January 2005 to July 
2008) was used. An open-cohort design was used to classify patients’ observation into
mutually-exclusive periods of branded versus generic use of lamotrigine. Periods of 
generic use were further stratiﬁ ed into single-generic, multiple-generic use, and switch-
back-cohort. Published results from Québec’s provincial health care-plan (RAMQ) 
from April 1998 to July 2006 were used as comparator. Patients with at least one 
diagnosis for epilepsy (ICD-10: G40.x) and at least one prescription of Lamotrigine 
(ATC-N03A0) were selected. RESULTS: A total of 1,171 patients (674 female
(57.5%), mean age 39.0, SD 17.4) were observed in the German data. Compared to 
the RAMQ database, we found a similar distribution of patients’ demographics, 
periods of brand use and generic switching. In the switch-group, 30.3 % of patients
switched back to branded lamotrigine. There was a statistically signiﬁ cant difference
between brand and generic periods for mean (paired t-test, p  0.0001) and median 
(sign-test, p  0.0001) daily dose. In contrast, the group switching from branded to
generic and back to branded lamotrigine showed no signiﬁ cant difference in the mean 
(p  0.4482) and median daily dose (p  0.7744). CONCLUSIONS: Lamotrigine 
patients in Germany switching from brand to generic lamotrigine experienced similar
clinical consequences of generic substitution, as reported previously, also for other 
AEDs. Given the same characteristics as here, results can be transferred to a different 
population. Therefore, we expect comparable clinical consequences and switch back 
patterns for topiramate generic substitution in Germany.
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OBJECTIVES: To compare cost of care for interferon beta (IFNB)-1a subcutaneous 
(SC) and natalizumab in patients with multiple sclerosis (MS). METHODS: In this 
post hoc analysis, eligible patients (18 and 65 years) had an MS diagnosis in a
national managed care database, q1 new medical or prescription claim for IFNB-1a 
SC or natalizumab during the July 1, 2006 to December 31, 2006 selection period,
and were continuously eligible for 12 months before and after the initial disease-
modifying drug (DMD) claim in the selection period. Managed care costs represented
both total and component costs. A propensity score was calculated as the probability 
of being in either treatment group from preperiod variables (eg, age, sex, region). 
Analysis of covariance was used to evaluate total and component costs by treatment 
cohort. RESULTS: A total of 421 patients (IFNB-1a SC  222, natalizumab  199) 
met study criteria. Most patients were women (IFNB-1a SC, 77.9%; natalizumab, 
74.4%), but were older in the natalizumab group (mean [SD] 45.5 [9.7] y vs 42.2 
[10.7] y). DMD use differed by region, and more natalizumab patients were enrolled 
in HMOs (43.2% vs 32.4%). The percentage of patients with no evidence of DMD
use in the preperiod was 26.6% for natalizumab and 63.5% for IFNB-1a SC. Least
square (LS) means differences between IFNB-1a SC and natalizumab for total and 
prescription costs were a function of the number of days of exposure. At the average 
exposure of 290 days, total LS mean cost for IFNB-1a SC and natalizumab were 
$26,433 and $35,980, respectively (P  0.0001). Prescription costs were signiﬁ cantly
higher for natalizumab compared with IFNB-1a SC ($26,775 vs $20,187; P  0.0001). 
Outpatient costs were signiﬁ cantly greater for natalizumab patients ($8640) than for
IFNB-1a SC patients ($4930; P  0.0001). CONCLUSIONS: Patients initiated on 
natalizumab had greater total, prescription, and outpatient costs than did patients 
initiated on IFNB-1a SC.
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OBJECTIVES: To assess the impact of headache frequency on health care utilization,
medication use, productivity loss, and total costs. METHODS: The American
Migraine Prevalence and Prevention (AMPP) Study is a 5-year, national, longitudinal
